Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia

Eltrombopag has been shown to be noninferior to intravenous immunoglobulin (IVIG) for improving perioperative platelet counts in patients with immune thrombocytopenia (ITP) in a randomized trial; thus, cost is an important factor for treatment and policy decisions. We used patient-level data from th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaur, Manraj N., Arnold, Donald M., Heddle, Nancy M., Cook, Richard J., Hsia, Cyrus, Blostein, Mark, Jamula, Erin, Sholzberg, Michelle, Lin, Yulia, Kassis, Jeannine, Larratt, Loree, Tinmouth, Alan, Carruthers, Julie, Li, Na, Liu, Yang, Xie, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Platelets and Thrombopoiesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945289/
https://www.ncbi.nlm.nih.gov/pubmed/34781363
http://dx.doi.org/10.1182/bloodadvances.2021005627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945289/
https://www.ncbi.nlm.nih.gov/pubmed/34781363
http://dx.doi.org/10.1182/bloodadvances.2021005627

Ejemplares similares